Retrospective Observational Study on the Incidence and Treatment Course of Arrhythmias and Conduction Disturbances in Patients with Cardiac Amyloidosis in Shimane University Hospital

Retrospective Observational Study on the Incidence and Treatment Course of Arrhythmias and Conduction Disturbances in Patients with Cardiac Amyloidosis in Shimane University Hospital - CARHYTHM-S

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061396

Enrollment

Registered

2026-04-27

Start date

2026-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Amyloidosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with cardiac amyloidosis at Shimane University Hospital between January 1, 2020 and January 31, 2026. 2. Patients with confirmed AL or ATTR amyloidosis. 3. Patients who received or were scheduled to receive disease-modifying therapy, including tafamidis, acoramidis, or vutrisiran.

Exclusion criteria

Exclusion criteria: Patients with concomitant cardiac diseases other than cardiac amyloidosis, such as ischemic heart disease or valvular disease, in whom arrhythmias or conduction disturbances are judged to be clearly attributable to causes other than cardiac amyloidosis.

Design outcomes

Primary

Measure	Time frame
This study aims to elucidate the clinical characteristics of disease status in patients with AL or transthyretin (ATTR) cardiac amyloidosis, with particular emphasis on arrhythmias (tachyarrhythmias and bradyarrhythmias) and conduction disturbances, and to retrospectively evaluate the clinical course before and after the initiation of disease-modifying therapies, including tafamidis, acoramidis, and vutrisiran.	—

Measure

Time frame

This study aims to elucidate the clinical characteristics of disease status in patients with AL or transthyretin (ATTR) cardiac amyloidosis, with particular emphasis on arrhythmias (tachyarrhythmias and bradyarrhythmias) and conduction disturbances, and to retrospectively evaluate the clinical course before and after the initiation of disease-modifying therapies, including tafamidis, acoramidis, and vutrisiran.

—

Countries

Japan

Contacts

Public ContactMadoka Furuta

Shimane University Faculty of Medicine Cardiology

mdyamag@med.shimane-u.ac.jp0853202249

Outcome results